MedMatrix Rx
Daily 340B Morning Briefing
Johnson & Johnson imposes a new claims data requirement on 340B providers, effective September 15. The American Hospital Association urges CMS to reconsider its 2027 payment proposals, citing significant financial impacts on hospitals. Meanwhile, several federal lawsuits continue to shape the 340B landscape, with cases involving major pharmaceutical companies and state attorneys general.
EXECUTIVE SUMMARY
01
Johnson & Johnson mandates claims data submission for 340B discounts.
Starting September 15, Johnson & Johnson requires 340B providers to submit claims data or face pricing suspension.
Starting September 15, Johnson & Johnson requires 340B providers to submit claims data or face pricing suspension.
Source: Healthcare Dive
02
AHA opposes CMS’s 2027 payment proposals.
The American Hospital Association warns CMS that its 2027 payment proposals could cost hospitals over $600,000 annually.
The American Hospital Association warns CMS that its 2027 payment proposals could cost hospitals over $600,000 annually.
Source: Becker’s Hospital Review
03
Froedtert Memorial Lutheran Hospital sues CVS for $18M diversion.
Froedtert alleges CVS diverted $18 million in 340B savings through improper reimbursement practices.
Froedtert alleges CVS diverted $18 million in 340B savings through improper reimbursement practices.
Source: Becker’s Hospital Review
04
HRSA to launch 340B Rebate Model Pilot Program.
HRSA’s pilot program, launching January 2027, will test a rebate model to address nonduplication requirements.
HRSA’s pilot program, launching January 2027, will test a rebate model to address nonduplication requirements.
Source: Drug Channels
05
AAMC and AHA push for changes in 340B-related rules.
AAMC and AHA urge CMS to revise provisions affecting 340B pricing and drug price negotiation rules.
AAMC and AHA urge CMS to revise provisions affecting 340B pricing and drug price negotiation rules.
Source: Becker’s Hospital Review
06
Milwaukee hospital’s lawsuit against CVS highlights 340B challenges.
Froedtert Memorial Lutheran Hospital’s lawsuit against CVS shows ongoing disputes over 340B savings.
Froedtert Memorial Lutheran Hospital’s lawsuit against CVS shows ongoing disputes over 340B savings.
Source: Becker’s Hospital Review
07
NASP comments on CMS’s 340B payment changes.
NASP submitted comments on CMS’s proposed changes to 340B payments, focusing on reimbursement and compliance.
NASP submitted comments on CMS’s proposed changes to 340B payments, focusing on reimbursement and compliance.
Source: NASP
08
AbbVie faces legal challenges over 340B practices.
AbbVie is involved in multiple lawsuits related to 340B program practices. These cases reflect ongoing legal battles.
AbbVie is involved in multiple lawsuits related to 340B program practices. These cases reflect ongoing legal battles.
Source: CourtListener
09
Site-neutral payment concerns impact health system decisions.
Health systems are adjusting outpatient capacity investments due to site-neutral payment concerns.
Health systems are adjusting outpatient capacity investments due to site-neutral payment concerns.
Source: Becker’s Hospital Review
10
Pharmaceutical Research and Manufacturers of America v. Weiser continues.
The case addresses state-level 340B program challenges, with implications for pharmaceutical companies.
The case addresses state-level 340B program challenges, with implications for pharmaceutical companies.
Source: CourtListener
EXECUTIVE SUMMARY — KEY TAKEAWAYS
Most important 340B implication. Johnson & Johnson’s new claims data requirement for 340B discounts signals a tightening of compliance expectations across the pharmaceutical industry. This move may prompt other manufacturers to adopt similar policies, potentially leading to increased administrative burdens for 340B covered entities. The requirement highlights the ongoing tension between drug manufacturers and healthcare providers over program compliance and discount eligibility. As more manufacturers impose data submission mandates, covered entities may face challenges in maintaining compliance while ensuring access to discounted drugs.
Emerging risks.
- Hospitals may face increased financial strain from CMS’s proposed 2027 payment changes, impacting budgets significantly.
- Failure to comply with J&J’s claims data requirement could result in loss of 340B pricing for covered entities.
- Ongoing litigation involving major pharmaceutical companies may lead to adverse legal and financial outcomes for involved parties.
- Site-neutral payment policies could lead to strategic shifts in outpatient service investments by health systems.
Emerging opportunities.
- Covered entities can meet compliance with J&J’s data requirement to maintain access to 340B pricing benefits.
- Hospitals can actively participate in CMS’s rulemaking process to influence favorable outcomes in the 2027 payment proposals.
- Health systems can optimize outpatient service locations to align with site-neutral payment policies, potentially improving efficiency.
- Engaging in legal challenges may provide covered entities with opportunities to shape future 340B program interpretations.
Key actions for providers.
- Submit claims data promptly to comply with J&J’s 340B pricing requirements and avoid suspension.
- Review and respond to CMS’s 2027 payment proposals to mitigate financial impacts on hospital operations.
- Monitor ongoing litigation involving pharmaceutical companies to anticipate potential changes in 340B program practices.
- Evaluate outpatient service strategies in light of site-neutral payment concerns to ensure alignment with financial goals.
TOP STORIES
Johnson & Johnson imposes new 340B claims data requirement.
Healthcare Dive · September 14, 2026
- J&J requires 340B providers to submit claims data starting September 15.
- Noncompliance will lead to pricing suspension, with restoration upon data submission.
AHA urges CMS to reconsider 2027 payment proposals.
Becker’s Hospital Review · August 26, 2026
- AHA warns CMS’s proposals could cost hospitals over $600,000 annually.
- More than 500 hospitals may face repayments exceeding $1 million each year.
Froedtert Memorial Lutheran Hospital sues CVS for $18M.
Becker’s Hospital Review · August 31, 2026
- Froedtert alleges CVS diverted $18 million in 340B savings.
- The lawsuit highlights ongoing disputes over 340B program practices.
FEDERAL POLICY & REGULATORY DEVELOPMENTS
HRSA to launch 340B Rebate Model Pilot Program.
Drug Channels · August 25, 2026
- The pilot program will start on January 1, 2027.
- It aims to address nonduplication requirements under the Inflation Reduction Act.
AAMC and AHA push for changes in 340B-related rules.
Becker’s Hospital Review · August 26, 2026
- AAMC and AHA submitted comments to CMS on 340B pricing rules.
- They advocate for prospective application of Maximum Fair Price.
NASP comments on CMS’s 340B payment changes.
NASP · September 1, 2026
- NASP addresses reimbursement and compliance considerations in its comments.
- The focus is on preserving patient access and specialty pharmacy services.
340B PROGRAM DEVELOPMENTS
Johnson & Johnson requires claims data for 340B discounts.
Becker’s Hospital Review · September 11, 2026
- J&J’s policy applies to all covered entity types.
- Pricing suspension will begin at least five business days after final notice.
LITIGATION & ENFORCEMENT WATCH
| Court | Matter | Date |
|---|---|---|
| M.D. Fla. | The Elevance Health Companies, Inc. v. Senderra Rx Partners, LLC [source] | September 4, 2026 |
| D.D.C. | COREWELL HEALTH WILLIAM BEAUMONT UNIVERSITY HOSPITAL v. KENNEDY [source] | September 3, 2026 |
| D. Maryland | State of New York v. U.S. Department of Health and Human Services [source] | August 27, 2026 |
| E.D. Wis. | Froedtert Memorial Lutheran Hospital Inc v. CVS Health Corporation [source] | August 20, 2026 |
MANUFACTURER WATCH
| Manufacturer | Action | Date |
|---|---|---|
| Johnson & Johnson | Requires 340B providers to submit claims data to maintain discounts. [source] | September 14, 2026 |
WHAT TO WATCH NEXT
- Johnson & Johnson’s claims data requirement takes effect September 15, 2026. [source]
- HRSA’s 340B Rebate Model Pilot Program to launch January 1, 2027. [source]
- CMS’s final decision on 2027 payment proposals expected soon. [source]
- Ongoing court cases involving AbbVie and other pharmaceutical companies. [source]
End of briefing.
This briefing is provided for informational purposes only and does not constitute legal, regulatory, financial, or compliance advice. Automated summarization may contain errors or omissions, and source materials may change after publication. Recipients should independently verify all information against the cited primary sources before relying on it.
© 2026 MedMatrix Rx. All rights reserved.